Online Pharmacy US

PHILADELPHIA – The American Home Products National Settlement as amended and interpreted by the supervising judge discriminates against obese persons and runs counter to accepted medical practice, an unsuccessful claimant argues to the Third Circuit U.S. Court of Appeals (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability L itigation, MDL Do cket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. (more…)

PHILADELPHIA – The judge supervising the diet drug multidistrict litigation has, at the request of Plaintiffs’ Liaison Counsel (PLC), ordered expedited handling of Wyeth’s request that individual settlement amounts not be filed with common benefit fee documentation and th at the judge instead inspect settlement information in camera (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, (more…)

PHILADELPHIA – Wyeth argues that to allow two plaintiffs whose pulmonary arterial hypertension (PAH) does not meet the settlement’s definition of primary pulmonary hypertension (PPH) to go to trial would “render the . . . protections for which Wyeth bargained a nullity” (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, (more…)

PHILADELPHIA – The judge supervising the diet drug multidistrict litigation has ruled that a claimant’s failure to withdraw an improper opt-out suit against Wyeth was dismissed with prejudice, precluding her from later seeking settlement benefits (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. (more…)

PHILADELPHIA – Class counsel has respon ded to three unsuccessful pro se claimants, saying that the echocardiogram criteria in the American Home Products National Settlement Agreement were chosen as the most likely to demonstrate compensable injury levels for most claimants and that other methodologies would not have yielded a bett er result for the three objectors (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability (more…)

PHILADELPHIA – The American Home Products National Settlement as amended and interpreted by the supervising judge discriminates against obese persons and runs counter to accepted medical practice, an unsuccessful claimant argues to the Third Circuit U.S. Court of Appeals (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Do cket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, (more…)

PHILADELPHIA – The judge supervising the diet drug multidistrict litigation has ruled that a claimant’s failure to withdraw an improper opt-out suit against Wyeth was dismissed with prejudice, precluding her from later seeking settlement benefits (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. (more…)

PHILADELPHIA – Wyeth argues that to allow two plaintiffs whose pulmonary arterial hypertension (PAH) does not meet the settlement’s definition of primary pulmonary hypertension (PPH) to go to trial would “render the . . . protections for which Wyeth bargained a nullity” (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenflur amine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, (more…)

PHILADELPHIA – The judge supervising the diet drug multidistrict litigation has, at the request of Plaintiffs’ Liaison Counsel (PLC), ordered expedited handling of Wyeth’s request that individual settlement amounts not be filed with common benefit fee documentation and that the judge instead inspect settlement information in camera (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, (more…)

PHILADELPHIA – Class counsel has responded to three unsuccessful pro se claimants, saying that the echocardiogram criteria in the American Home Products National Settlement Agreement were chosen as the most likely to demonstrate compensable injury levels for most claimants and that other methodologies would not have yielded a better result for the three objectors (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability (more…)